- Strong growth in business
- €933 million in sales
- Up 19.5% as reported
- Up 8.1% like-for-like
- Sharp 34% improvement in
contributive operating income before non-recurring items lifted by
strong business momentum, the disciplined management of operating
expenses and the positive currency effect
- Sustained successful performance by
FilmArray®
- 510(k) FDA clearance of
VIDAS® 3
- Execution of the industrial
investment plan
- Confirmation of the 2015 financial
objectives
Alexandre Mérieux, Chief Executive Officer, said: "bioMérieux
delivered a solid performance in the first half of 2015, attesting
to its effective positioning as a specialist in the in vitro
diagnosis of infectious diseases. The strong dynamic observed
during the past 6 months reflects our broad geographic footprint
and our diversified portfolio of solutions, which was recently
enhanced with the acquisition of BioFire in molecular biology.
Against this backdrop, and despite the economic instability, we are
confident in our ability to reach our 2015 objectives."
Regulatory News:
The Board of Directors of bioMérieux (Paris:BIM), a world leader
in the field of in vitro diagnostics, met on August 28 under
the chairmanship of Jean-Luc Belingard and approved the
consolidated financial statements for the six months ended
June 30, 2015. The Statutory Auditors had performed a review
of the financial statements.
Audited
consolidated data
In € millions
H12015
H12014(1)
% changeas reported
Sales 933 781 +19.5%
Contributive operating income before non-recurring items(2)
122 91 +34.3% Operating income
103 78 +33.1%
Net
income of consolidated companies 59 51
+16.9% Earnings per share (in €)
1.51
1.28 +16.9%
(1) Adjusted for the application of IFRIC 21 – Levies, as shown
in appendix 1.(2) Contributive operating income before
non-recurring items corresponds to operating income before
non-recurring BioFire acquisition and integration costs and before
accounting entries relating to BioFire purchase price allocation.
Operating income before non-recurring items corresponds to
operating income before material, extraordinary and non-recurring
items, which are included in “other non-recurring income and
expenses from operations”.
FINANCIAL RESULTS
Sales1
Consolidated sales amounted to €933 million in the first half of
2015, up from €781 million in the year-earlier period. This
represented growth of 8.1% like-for-like with FilmArray® confirming
its role as a faster growth driver for the Group, adding
approximately 300 basis points to the gains generated by the other
bioMérieux lines. After changes in the scope of consolidation
related to the BioFire and CEERAM acquisitions, growth reached 9.1%
at constant exchange rates. Reported growth stood at 19.5%, lifted
by the €81 million (10.4%) positive effect of the increase in the
US dollar and other currencies against the euro over the
period.
Analysis of Sales
In € millions
Sales - 6 months ended June 30, 2014
781 Currency effect +81 +10.4% Organic growth (at constant
exchange rates and scope of consolidation) +63 +8.1%
}+9.1%
Change in scope of consolidation(1) +8 +1.0%
Sales - 6 months
ended June 30, 2015 933 +19.5%
(1) BioFire: sales from January 1 to January 15, 2015 excluded
from the organic growth calculation (acquisition date:
January 16, 2014)CEERAM: first-time consolidation of
sales from this technological start-up acquired in late December
2014.
Consolidated income statement
Lifted by a €35-million gain from favorable currency movements,
reported gross profit stood at €474 million in first-half 2015,
compared with €385 million in the prior-year period and
representing a gross margin of 50.8% of sales. At constant exchange
rates and scope of consolidation, gross margin came to an estimated
51.4%, up 210 basis points from first-half 2014. The improvement
was led by the robust 8.1% organic growth in sales, which raised
coverage of fixed costs, and by a more favorable product mix, both
of which were partly offset by the impact of provisions on
licensing agreements. Expenses committed by the Durham, NC site in
response to observations made by the US Food and Drug
Administration (FDA) declined gradually during the period, to
€12 million from €15 million a year earlier.
- Contributive operating income before
non-recurring items
Contributive operating income before non-recurring items ended
the first six months at €122 million or 13.1% of sales, versus
€91 million and 11.6% a year earlier. The growth reflected the
improvement in gross profit, a €6-million positive currency effect
and operating cost discipline at a time when the Company is
investing to maintain the success of FilmArray®.
- Selling, general and administrative
expenses totaled €254 million, or 27.3% of sales, compared
with €215 million and 27.6% in first-half 2014. The around
€19-million increase at constant exchange rates primarily reflected
the investment in the commercial development of the FilmArray®
line.
- Research and development outlays
amounted to €116 million and represented 12.4% of sales,
versus €100 million and 12.8% in the prior-year period. The
like-for-like increase primarily reflects the stepped-up R&D
commitment to FilmArray® and tight control over spending on the
other lines.
- Research tax credits amounted to €11
million, versus €14 million in first-half 2014, when they were
lifted by favorable adjustments in relation to prior years.
- "Other operating income", which mainly
comprises royalty income, was unchanged for the period, at €7.4
million.
1 Sales growth by region and by application is presented in
Appendix 2. The full first-half 2015 business review may be found
at www.biomerieux-finance.com.
- Operating income before
non-recurring items
BioFire acquisition expenses primarily include the depreciation
and amortization charged against identifiable assets acquired,
whose fair value was estimated as part of the purchase price
allocation process, as well as the impact of the retention plan
adopted in connection with the acquisition, representing a total of
€18 million for the period, versus €15 million in first-half 2014.
As a result, operating income before non-recurring items stood at
€104 million, compared with €76 million a year
earlier.
Operating income ended the first half at €103 million or
11.0% of sales, versus €77 million and 9.8% in the prior-year
period.
- Financial income and taxes
Cost of debt stood at €12 million, up €10 million from €2
million in first-half 2014, primarily due to the additional debt
contracted to acquire BioFire.
In first-half 2015, the interest expense on this financing
amounted to €8 million and the fair value of the hedging
instruments recognized in the income statement declined by €2
million. On the other hand, in first-half 2014, when euro interest
rates were declining, the finance cost was zero on a net basis, as
the €6 million in interest expense was offset by the unrealized
fair value gains on the hedging instruments.
The effective tax rate came to 34.1% at June 30, 2015, higher
than the first-half 2014 figure of 30.7%, which was restated for
the impact of IFRIC 21 and reduced by the favorable adjustments in
relation to prior years.
Given these conditions, net income rose to €59 million or 6.3%
of sales, from €51 million in first-half 2014.
Cash management and finance
EBITDA2 amounted to €179 million in the first half of 2015,
compared with €141 million in the prior-year period,
reflecting the solid growth of contributive operating income before
non-recurring items.
While stable in first-half 2014, operating working capital
requirement rose in first-half 2015, by €62 million, under the
combined impact of:
- Movements of around €33 million in
trade receivables, down €2 million from the movements recorded in
first-half 2014 when €13 million in past-due Spanish receivables
were paid.
- A rise in the value of inventories that
was almost €20-million higher than the increase recorded in
first-half 2014, in particular at the Durham, NC site, due to the
return to satisfactory production conditions in the blood culture
bottle unit, and the Salt Lake City, UT facility, where FilmArray®
inventory is being rebuilt after the winter flu epidemic.
- Trade payables were down to
€37 million at June 30, 2015, compared with a €9-million
increase a year earlier, due to slight differences in payment
schedules from one month to the next, which had no impact on days
sales outstanding.
As expected, capital expenditure outlays rose steeply over the
period, to €86 million including €67 million in
industrial capital expenditure versus €56 million and €42
million respectively in first-half 2014. The outlays were primarily
committed to installing a new BacT/ALERT® blood-culture bottle line
at the Durham, NC site, building the new BioFire facility in Salt
Lake City, UT and extending the Marcy l’Etoile, France site with a
new VIDAS® strip packaging line.
In light of the above, free cash flow3 amounted to
€24 million for the period versus €62 million in first-half
2014.
2 EBITDA corresponds to the aggregate of contributive operating
income before non-recurring items, depreciation and amortization.3
Free cash flow corresponds to cash generated from operations, net
of cash used in investing activities.
Against a backdrop of significant operational and industrial
investment, net debt amounted to €274 million at June 30,
2015, versus €249 million at December 31, 2014. Dividends
totaling €39.5 million were paid in June 2015, an amount virtually
unchanged from 2014.
The Company has €300 million in seven-year bonds, placed with
institutional investors in October 2013. It also has an undrawn
€350-million syndicated line of credit expiring on May 20,
2019. Lastly, on March 31, 2015, it signed a 12-year, €45-million
lease financing agreement to fund the extension of the Marcy
l'Etoile, France site.
OTHER INFORMATION
The installed base at June 30, 2015 stood at
approximately 81,200 instruments, including 1,867 FilmArray®
instruments. This represented an increase of around 1,700 new
instruments over the period, of which 266 FilmArray® units.
The Company had a total of 9,258 full-time-equivalent
employees and temporary staff as of June 30, 2015,
compared with 8,935 at December 31, 2014.
SIGNIFICANT EVENTS OF FIRST-HALF 2015
During the first quarter, the new generation FilmArray®
system, FilmArray® 2.0, was cleared by the FDA and
CE-marked. The main feature of this compact instrument is its
higher throughput, which allows laboratories to process up to 175
samples in a day. The solution accommodates up to eight
FilmArray® 2.0 units operated by a single computer and is
capable of connecting to Laboratory Information Systems (LIS).
In addition, bioMérieux broadened its offering in molecular
biology, with the introduction of a new version of the
NucliSENtral® middleware, and in immunoassays, with
the launch of the bioNexia® Legionella
rapid diagnostic test that detects the presence of Legionella
pneumophila serogroup 1, the most commonly identified pathogen in
Legionnaires' disease.
- De novo application submitted
for the FilmArray® Meningitis/Encephalitis
Panel
In April 2015, BioFire submitted a de novo classification
request to the US Food and Drug Administration (FDA) for the
FilmArray® Meningitis/Encephalitis (ME) panel.
The pioneering FilmArray® ME panel addresses a critical, unmet need
for quickly identifying central nervous system infections by
utilizing a comprehensive panel to test cerebrospinal fluid (CSF)
for the most common bacteria, viruses and fungi responsible for
community-acquired meningitis or encephalitis. A one-hour or so
turnaround time has the potential to reduce mortality and morbidity
from these devastating diseases and to positively impact patient
management. FilmArray® ME will only be available for sale once the
FDA has completed its process. Subject to FDA clearance, the panel
will be the fourth clinical diagnostic test to run on the
FilmArray® system, making its syndromic menu the largest
commercially available for a multiplexing platform.
- Production and quality
system
In February 2015, France's ANSM drug regulatory agency issued an
injunction letter requesting that bioMérieux complete, within 12
months, the work required to bring into compliance certain
production units at the site in Craponne, France. Based on
discussions with the ANSM, an action plan was defined in April to
address this request and is now being deployed.
In June 2015, the FDA re-inspected the site in St. Louis,
Missouri and reviewed all of the corrective actions implemented in
response to the October 2014 Warning Letter. It determined that
there were no repeat observations as regards the Letter. Following
the inspection, the FDA issued two new observations, which
bioMérieux is already addressing with a corrective action plan.
Also in the United States, the Durham, NC site continued to
deploy the action plans defined with the FDA to address its
observations and prepare for the coming re-inspections.
To refocus its commercial offering, bioMérieux has initiated a
plan to dispose of its microplate immunoassay product line,
which it deems to be non-strategic for the Company. After talks
with potential buyers proved inconclusive, the production and sale
of certain product lines will be terminated as of year-end 2015. As
a result, €8 million in assets previously recorded under "Assets
held for sale" have been reclassified under their initial headings
as of June 30, 2015
The search for a partner to step up bioTheranostics's
growth was still underway at period-end.
SUBSEQUENT EVENTS
- VIDAS® 3 cleared by
the FDA
On July 9, bioMérieux received 510(k) clearance from the FDA to
market VIDAS® 3, the new generation of VIDAS® that further enhances
the range of automated VIDAS® and mini VIDAS® immunoassay
instruments in the United States. VIDAS® 3 reinforces the ease of
use that has made the VIDAS® range so popular. Thanks to its
design, tests can be performed on demand, individually or in
series, 24 hours a day and seven days a week. As a result, it is
perfectly suited to centralized as well as satellite laboratories,
bringing both versatility and reliability to healthcare
professionals who are able to optimize their workflows and
guarantee the quality of biological testing.
- Non-exclusive license agreement
signed with LBT Innovations Ltd
On August 27, 2015, a non-exclusive license agreement was
signed with LBT Innovations for the MicroStreak® technology used in
the PREVI® Isola automated culture-plate streaking system. The
agreement terminates the exclusive license initially granted in
2007 and leaves each company free to independently pursue its own
developments in the field of microbiology lab automation.
bioMérieux will retain the right to maintain the installed base of
PREVI® Isola systems, including the supply of patented inoculation
applicators, but will no longer market new PREVI® Isola systems
after August 2016.
- FilmArray® BioThreat-E
for the detection of the Ebola virus receives WHO Emergency Use
Assessment and Listing
In view of the unprecedented outbreak of Ebola virus raging in
West and Central Africa since summer 2014, the World Health
Organization (WHO) introduced an emergency mechanism to assess in
vitro diagnostics that will be used to diagnose Ebola virus
disease. As a result, the FilmArray® BioThreat-E test for the
detection of the Ebola virus was accepted for UN procurement in
August 2015. The FilmArray® BioThreat-E test enables a simple,
rapid and reliable diagnosis of the Zaire Ebola virus involved in
the current epidemic.
2015 OBJECTIVES
Based on the current business outlook, the Company maintains its
objective of reporting between 4.5% and 6.5% organic
growth in sales in 2015, at constant exchange rates and scope
of consolidation. It is also maintaining its contributive
operating income before non-recurring items target of between
€240 million and €265 million for the year. In an
unstable economic environment, bioMérieux remains confident about
the strength of the performance expected for 2015 in relation to
the objectives set.
Jean-Luc Belingard, Chairman, concluded: "The market we
serve continues to expand. In particular, the fight against
microbial resistance is now considered a global public health
priority, supported by a wide range of government initiatives in
which we are actively participating. As a result, backed by its
extensive international presence and broader business portfolio,
bioMérieux will continue to assertively deploy its strategy and its
operational action plan, the validity of which is confirmed by the
solid results announced today."
INVESTOR CALENDAR
Third-quarter sales: October 22, 2015, before start of
trading
The above forward-looking statements are based, entirely or
partially, on assessments or judgments that may change or be
modified, due to uncertainties and risks related to the Company's
economic, financial, regulatory and competitive environment,
notably those described in the 2014 Registration Document.
Accordingly, the Company cannot give any assurance nor make any
representation as to whether the objectives will be met. The
Company does not undertake to update or otherwise revise any
forecasts or objectives presented herein, except in compliance with
the disclosure obligations applicable to companies whose shares are
listed on a stock exchange.
ABOUT BIOMÉRIEUX
Pioneering Diagnostics
A world leader in the field of in vitro diagnostics for 50
years, bioMérieux is present in more than 150 countries
through 42 subsidiaries and a large network of distributors. In
2014, revenues reached €1,698 million with 88% of sales
outside of France.
bioMérieux provides diagnostic solutions (reagents, instruments,
software) which determine the source of disease and contamination
to improve patient health and ensure consumer safety. Its products
are used for diagnosing infectious diseases and providing high
medical value results for cancer screening and monitoring and
cardiovascular emergencies. They are also used for detecting
microorganisms in agri-food, pharmaceutical and cosmetic
products.
bioMérieux is listed on the NYSE Euronext Paris stock market
(Symbol: BIM – ISIN: FR0010096479).
Corporate website: www.biomerieux.com
Investor website: www.biomerieux-finance.com
Appendix 1: Adjustments Following Application of
IFRIC 21
Key factors impacted 06/30/2014
12/31/2014 in millions of euros
Published
IFRIC 21 Restated Published
IFRIC 21 Restated
Total equity of the Group
at January 1st
1,267.3 0.8 1,268.1 1,267.3 0.8
1,268.1 Total other comprehensive income
(expense)
-7.0 -7.0 24.0 24.0 Net income for the year 52.5 -1.9 50.6 135.5
135.5 Total comprehensive income 45.5 -1.9 43.6 159.4 159.4 Other
movements -39.6 -39.6 -38.1 -38.1
Total equity of the Group
at closing
1,273.2 -1.1 1,272.2 1,388.6 0.8
1,389.4
Total balance
sheet at closing 2,327.5 -0.5 2,327.0 2,580.5 -0.5 2,580.0 Other
operating payables 235.0 1.9 236.9 251.3 -1.3 250.0 Deferred tax
assets 58.0 -0.5 57.5 86.0 -0.5 85.5 Current tax 14.2 -1.2 13.0
15.4 15.4 Earnings per share 1.32 -0.04 1.28
3.42 3.42
Appendix 2: Sales by Region and Application
Sales by Region
In € millions
H12015 H12014 % changeas
reported
% changeat constant exchange rates and scope
of consolidation Europe(1)
414.9 402.5
+3.1%
+1.8% Americas
358.4 249.7 +43.5%
+18.9% North America
291.8 190.7 +53.0%
+21.8%
Latin America
66.6 59.0 +12.8%
+9.3% Asia-Pacific
148.8 120.3 +23.6%
+6.6%
Total sales from the regions 922.1
772.6 +19.4%
+8.0% bioTheranostics
8.9 4.7 +90.0%
+54.8%
R&D-related revenues
2.2 3.4
TOTAL 933.2 780.7
+19.5%
+8.1%
(1) Including the Middle East and Africa.
Sales by Application
In € millions
H12015 H12014 % changeas
reported
% changeat constant exchange rates and scope
of consolidation
Clinical Applications 740.5
615.5 +20.3%
+8.6% Microbiology
416.3 364.9 +14.1%
+5.0% Immunoassays(1)
210.2
185.0 +13.6%
+4.7% Molecular Biology(2)
107.9 57.7
+86.9%
+48.8% Others
6.1 7.9 -23.0%
-25.7%
Industrial Applications 172.8 152.6 +13.2%
+4.4% bioTheranostics
8.9 4.7 +90.0%
+54.8%
BioFire Defense
8.7 4.5 +95.1%
+52.3% R&D-related
revenue
2.2 3.4
TOTAL 933.2 780.7 +19.5%
+8.1%
(1) Including VIDAS®: up 7.4% like-for-like over the period(2)
Including €67 million in BioFire Diagnostics sales for the
period
Appendix 3: bioMérieux Consolidated Financial
Statements at June 30, 2015
bioMérieux
CONSOLIDATED INCOME STATEMENT
In millions of euros
06/30/2015
12/31/2014
(a)
06/30/2014
(a)
Net Sales 933.2
1,698.4 780.7 Cost of sales
-459.6 -853.9 -395.8
Gross profit 473.6 844.5
384.9 Other operating income (b)
18.7 41.1
21.5 Selling and marketing expenses -176.4 -311.3
-150.9 General and administrative expenses -77.9 -141.7 -64.9
Research and development expenses -115.9 -205.8 -99.8
Total
operating expenses -370.2
-658.8 -315.6 Contributive
operating income 122.1 226.8
90.9 Fees and amortization of the
BioFire purchase price (b) -18.2 -23.9 -14.6
Operating income
before non-recurring items 103.9
202.9 76.3 Other non-recurring
income (expenses) (b) -0.8 0.6 1.2
Operating income
103.1 203.6 77.5
Cost of net financial debt -12.1 -7.2 -1.7 Other financial
items -1.0 -8.9 -2.4 Income tax -30.7 -51.7 -22.5 Investments in
associates -0.2 -0.3 -0.2
Net income of consolidated
companies 59.1 135.5
50.6 Attributable to non-controlling interests
-0.4 0.6 0.2
Attributable to the parent company
59.6 134.9 50.4
Basic net income per share 1.51 € 3.42 € 1.28 €
Diluted net income per share 1.51 € 3.42 €
1.28 €
(a) Financial statements since January 1, 2014 have been
adjusted for the impact of applying IFRIC 21.(b) Given the scale of
the BioFire acquisition, the related fees have been broken out from
operating income before non-recurring items and shown on a separate
line, so as to give a better view of operating income.
bioMérieux
CONSOLIDATED BALANCE SHEET
ASSETS
(in millions of euros)
06/30/2015 12/31/2014
(a)
06/30/2014
(a)
Intangible assets 476.6 460.1 395.8 Goodwill
455.0 437.8 442.1 Property, plant and equipment 505.4 486.9 429.0
Financial assets 39.7 35.1 33.7 Investments in associates 0.3 0.5
0.2 Other non-current assets 21.7 21.9 21.9 Deferred tax assets
93.7 85.5 57.5
Non-current assets 1,592.3
1,527.8 1,380.2 Inventories and work in
progress 360.1 299.2 302.6 Accounts receivable 430.6 449.3 398.7
Other operating receivables 96.3 82.5 92.2 Tax receivable 12.2 21.0
3.8 Non-operating receivables 11.1 19.6 10.1 Cash and cash
equivalents 108.9 119.7 95.1
Current assets 1,019.3
991.4 902.5 Assets held for sale 62.5
60.8 44.3 TOTAL ASSETS 2,674.2
2,580.0 2,327.1
LIABILITIES AND SHAREHOLDERS' EQUITY
(in millions of euros)
06/30/2015 12/31/2014
(a)
06/30/2014
(a)
Share capital 12.0 12.0 12.0 Additional paid-in capital
& Reserves 1,362.1 1,234.8 1,203.2 Net income for the year 59.6
134.9 50.4
Shareholders' equity 1,433.7
1,381.7 1,265.5 Non-controlling
interests 7.9 7.8 6.6 Total equity
1,441.6 1,389.4 1,272.2 Net financial
debt - long-term 305.3 305.7 305.6 Deferred tax liabilities 156.6
145.1 124.5 Provisions 106.9 105.4 83.7
Non-current
liabilities 568.8 556.2 513.9 Net
financial debt - short-term 80.2 63.5 97.7 Provisions 17.5 11.1
11.8 Accounts payable 157.8 188.9 145.2 Other operating liabilities
269.2 250.0 236.9 Tax liabilities 26.4 15.4 13.0 Non-operating
liabilities 86.3 81.4 20.1
Current liabilities 637.4
610.2 524.6 Liabilities related to assets
held for sale 26.4 24.2 16.5 TOTAL
LIABILITIES AND SHAREHOLDERS' EQUITY 2,674.2
2,580.0 2,327.1
(a) Financial statements since January 1, 2014 have been
adjusted for the impact of applying IFRIC 21.
Balance sheet items do not include the corresponding assets and
liabilities of bioTheranostics, which have been reclassified as
either "Assets held for sale or "Liabilities related to assets held
for sale".
bioMérieux
CONSOLIDATED CASH FLOW
STATEMENT
In millions euros
06/30/2015 06/30/2014 Net income of
consolidated companies 59.1 52.5 - Investments in
associates 0.2 0.2 - Cost of net financial debt 12.1 1.7 - Other
financial items 1.0 2.4 - Current income tax expense 30.7 23.7 -
Operating depreciation and provisions on assets 56.7 46.9 -
Non-recurring items 19.0 13.4
EBITDA (before non-recurring
items) 178.8 140.9 Other non current operating
gains/losses
(w/o exceptionnal depreciations, assets
losses and capital gains/losses)
0.0 -9.9 Other financial items
(w/o accruals & disposal of financial
assets)
-1.0 -2.4 Operating provisions for risks and contingencies 2.9 1.6
Change in fair value of financial instruments -1.5 -4.4 Share-based
payments 0.4 0.4
Elimination of other gains and losses without
any impact on cash or operations 0.8 -14.7
Increase in inventories -45.4 -27.0 Change in trade receivable 32.7
35.2 Change in trade payable -37.0 8.5 Change in other operating
working capital -12.1 -16.2
Change in operating working
capital -61.8 0.5 Other non operating working
capital -4.6 -3.8 Change in non-current assets 1.9 2.7
Other
cashflows from operation -64.5 -0.6 Income tax
paid -5.5 -18.5 Net cash flow
from operations 109.6 107.1
Purchase of property, plant and equipment -86.1 -56.1 Proceeds on
fixed asset disposals 13.1 13.3 Purchase of financial assets /
Disposals of financial assets -6.1 -0.9 Impact of changes in the
scope of consolidation -0.5 -353.1
Net cash flow
from (used in) investment activities -79.6
-396.8 Increase in capital 0.0 0.0 Purchases and proceeds of
treasury stocks -0.8 -0.3 Dividends to shareholders -39.5 -39.5
Cost of net financial debt -12.1 -1.7 Change in confirmed financial
debt 15.2 -0.5
Net cash flow from (used in)
financing activities -37.2 -42.0
Net change in cash and cash equivalents -7.1
-331.7 Net cash and cash equivalents at the
beginning of the year 103.9 414.9
Impact of currency changes on net cash and cash equivalents
-2.0 -1.2
Net cash and cash equivalents at the end of the
year 94.8 82.0
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150830005018/en/
Investor RelationsbioMérieuxSylvain Morgeau, +33
(0)4 78 87 22 37investor.relations@biomerieux.comorMedia
RelationsbioMérieuxAurore Sergeant, +33 (0)4 78 87 54
75media@biomerieux.comorImage SeptLaurence Heilbronn, +33
(0)1 53 70 74 64lheilbronn@image7.frorClaire Doligez, +33 (0)1 53
70 74 48cdoligez@image7.fr
Biomerieux (EU:BIM)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Biomerieux (EU:BIM)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024
